| |
| Device | FoundationOne Liquid CDx (F1 Liquid CDx) |
| Generic Name | Next generation sequencing oncology panel, somatic or germline variant detection system |
| Applicant | Foundation Medicine, Inc. 400 Summer St. Boston, MA 02210 |
| PMA Number | P190032 |
| Supplement Number | S007 |
| Date Received | 08/29/2022 |
| Decision Date | 09/21/2022 |
| Product Code |
PQP |
| Advisory Committee |
Pathology |
| Supplement Type | Special (Immediate Track) |
| Supplement Reason | Labeling Change - Indications/instructions/shelf life/tradename |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approved removal of the companion diagnostic indication for F1Liquid CDx to identify patients with ovarian cancer harboring BRCA1 or BRCA2 alterations for treatment with rucaparib. |